Key result
Hypertension affects ~33% of Chinese adults, with persistently low treatment and control rates.
Why the study?
Hypertension remains a major public health challenge in China, requiring improved prevention strategies and optimized control measures accounting for regional and age-related differences.
Meta-Analysis (n=465,805)
Hypertension remains a major public health challenge in China with a high prevalence of 33.1% and persistently low treatment (32.8%) and control (14.9%) rates, highlighting the need for improved management strategies.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Persistent management gaps in China warrant targeted strategies; extends recent prevalence data and leaves open optimal interventions.
BACKGROUND: Hypertension is a leading cause of cardiovascular and cerebrovascular disease-related morbidity and mortality. This study aimed to investigate the prevalence, treatment rate and control rate of hypertension among Chinese adults from 2019 to the present through a meta-analysis, providing evidence for the development of strategies and measures for hypertension prevention and control at the national level. METHODS: We systematically searched PubMed, Embase, The Cochrane Library, CNKI, Wanfang and VIP to identify cross-sectional studies published from 2019 onwards that reported the prevalence, treatment rate and control rate of hypertension among Chinese adults aged ≥ 18 years. Study quality was assessed using a measurement tool developed by the U.S. Agency for Healthcare Research and Quality (AHRQ). Statistical analyses were performed using Stata 18.0. Pooled prevalence, treatment, and control rates were calculated via random-effects models, with meta-regression analysis and subgroup analyses conducted to assess heterogeneity. RESULTS: Twenty-seven studies involving 465,805 participants were included. The pooled age-standardized rates (2016-2022) were as follows: hypertension prevalence, 33.1% (95% CI: 29.3%, 37.0%); treatment rate, 32.8% (95% CI: 28.9%, 36.7%); and control rate, 14.9% (95% CI: 11.1%, 18.7%). Geographically, prevalence was highest in Northeast China (47.3%) and lowest in the West (33.3%), while the control rate showed an inverse pattern (West: 19.6%; Northeast: 12.6%) (both p < 0.001). Compared with rural residents, urban residents had a higher treatment rate (49.2% vs. 38.1%, p = 0.008). All three rates increased with age, reaching 59.4%, 42.9%, and 16.8% for prevalence, treatment, and control rates, respectively, in adults aged ≥ 60 years. Men had a higher prevalence than women (39.5% vs. 33.7%, p = 0.038), whereas women had a higher treatment rate (47.4% vs. 41.1%, p = 0.011). CONCLUSION: Hypertension remains a major public health challenge in China. It is essential not only to improve hypertension prevention strategies but also to optimize hypertension control measures while accounting for regional variations and age-related differences.
Qi et al. (2026) conducted a meta-analysis in Hypertension (n=465,805). Chinese adults was evaluated on Age-standardized hypertension prevalence (95% CI 29.3-37.0). Among Chinese adults from 2016 to 2022, the pooled age-standardized hypertension prevalence was 33.1%, with treatment and control rates remaining low at 32.8% and 14.9%, respectively.
Synapse has enriched 10 related papers. Consider them for comparative context: